Hims & Hers Health, Inc. (NYSE:HIMS) is one of the 12 Most Shorted Stocks to Buy in 2026. On March 11, Barclays analyst Glen Santangelo lifted its price objective on the company’s stock to $29 from $25, while keeping an “Overweight” rating. The analyst highlighted that a strong increase in share price after the Novo Nordisk agreement reflects a significant market opportunity.

Additionally, it also demonstrates the removal of legal overhang for Hims & Hers Health, Inc. (NYSE:HIMS)’s stock. As per the firm, the broader market has been underappreciating the company’s opportunity from new products.

Notably, in a different release, Hims & Hers Health, Inc. (NYSE:HIMS) announced a collaboration with Novo Nordisk as part of a new strategy for weight loss care treatments involving GLP-1s. In the US, the company aims to offer GLP-1 customers access to a broad assortment of medications that are FDA-approved, and provide compounded semaglutide via the platform on a limited scale.

Hims & Hers Health, Inc. (NYSE:HIMS) is a consumer-first health and wellness platform, connecting consumers to licensed healthcare professionals.

While we acknowledge the potential of HIMS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best FMCG Stocks to Invest In According to Analysts and 11 Best Long-Term Tech Stocks to Buy According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.